Anti-GluN1 Antibody Development for Stroke

Glutamate receptors have been studied extensively to improve stroke treatment. Several lines of experimental evidence suggest the possibility of using active immunization against the N-methyl-d-aspartate receptor (NMDAR) as a preventive vaccination and passive immunization to extend the time window for tissue-type plasminogen activator (tPA) thrombolysis. Unfortunately, immunotherapy targeting NMDARs has not been successful in clinical practice. Using an adeno-associated virus as a vector, researchers generated autoantibodies against the GluN1 subunit of the NMDAR in rats. After vaccination, the antibody was able to cross the blood-brain barrier (BBB) and reduce infarct volume in a permanent MCAO model. This provided an idea for the development of monoclonal antibodies against the NMDA receptor subunit.

Fig. 1. NMDAR-ab in the blood is discovered in anti-NMDAR encephalitis patients, healthy individuals, and patients with schizophrenia. (Gong et al., 2023)

Our Anti-GluN1 Antibody Development Services

As a leading CRO in the field of stroke, Ace Therapeutics offers comprehensive anti-GluN1 antibody development services. Our experienced team of experts helps clients develop effective anti-GluN1 antibodies using technology platforms such as antibody engineering, high-throughput screening.

From target identification to preclinical efficacy evaluation, Ace Therapeutics offers one-stop services for all your anti-GluN1 antibody development needs, ensuring seamless project management and efficient timelines.

Discovery and Optimization of Anti-GluN1 Antibodies

We construct libraries and perform multiple rounds of screening to find antibodies that specifically bind GluN1. We can also use DNA or RNA sequences encoding GluN1 as immunogens to induce the production of antibodies against GluN1 by genetic immunization. Anti-GluN1 antibodies are rigorously optimized to enhance their binding affinity, specificity, and neutralizing ability.

Preclinical Studies of Anti-GluN1 Antibodies in Animal Models of Stroke

We provide reliable in vivo models of stroke to evaluate the safety, efficacy, and pharmacokinetic properties of anti-GluN1 antibodies.

• Infarct volume measurement
• Pathologic detection of brain tissue damage
• Assessment of BBB leakage
• Platelet aggregation assay
• Longitudinal MRI studies (cerebral blood flow assays)
• Neurological deficit testing
• Pharmacokinetics and safety evaluation
• Mechanism of action studies

Ace Therapeutics' anti-GluN1 antibody development services are multifaceted, utilizing a range of advanced technologies and methodologies to help clients develop high-quality and effective therapeutic antibodies for stroke. If you are interested in our services, please do not hesitate to contact us!

1. Gong, X., et al. (2023). Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis. Frontiers in Neurology, 14, 1283511.